Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Stage 4 NBL with MYC-N amplification and 1p36 deletion was diagnosed in an 11 months old girl.
|
31441848 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Rare MYC-amplified Neuroblastoma With Large Cell Histology.
|
29426276 |
2019 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma.
|
31406244 |
2019 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that MELK is a direct transcription target of MYCN and MYC in NB, and MYCN increases MELK expression via direct promoter binding.
|
29416794 |
2018 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
N6,2'-O-dibutyryladenosine 3':5'cyclic monophosphate (Bt2cAMP) inhibited neuroblastoma cell growth by inhibiting c-MYC and HDAC8 expression and activating caspase 3.
|
30237861 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that epigenetic and posttranslational inhibition of MYC/MYCN-driven pathways may have significant clinical efficacy against neuroblastoma.
|
30153557 |
2018 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Specific inhibition of hyperactive rRNA synthesis and protein translation was shown to be an effective way to suppress MYC/MYCN protein expression and neuroblastoma growth.
|
29464082 |
2018 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data implicate tissue-specific enhancers in defining often highly tumor-specific 'MYC target gene signatures' and identify disruption of the MYCN enhancer regulatory axis as a promising therapeutic strategy in neuroblastoma.
|
29379199 |
2018 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis of human neuroblastoma tumor specimens revealed that MYC up-regulation correlates with markers of TAM infiltration.
|
29207662 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This hypothesis-driven systems bioinformatics work offered novel insights into the PRC2-mediated tumor cell growth and differentiation in neuroblastoma, which may exert oncogenic effects together with MYC regulation.
|
28984200 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYC and MYCN control the expression of PD-L1 in neuroblastoma cells both <i>in vitro</i> and <i>in vivo</i> Consistently, abundance of PD-L1 transcript correlates with MYC expression in primary neuroblastoma.<b>Conclusions:</b> The combination of PD-L1 and HLA class I represents a novel prognostic biomarker for neuroblastoma.
|
28270499 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study implicates the role of BORIS/CTCFL in maintenance of stemness and in transition from mesenchymal to epithelial state in MYC amplified neuroblastoma IMR-32 cells.
|
28104398 |
2017 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma.
|
29207623 |
2017 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYC coordinately regulates polyamine homeostasis as these essential cations support MYC functions, and drugs that antagonize polyamine sufficiency have synthetic-lethal interactions with MYC Neuroblastoma is a lethal tumor in which the MYC homologue MYCN, and ODC1, the rate-limiting enzyme in polyamine synthesis, are frequently deregulated so we tested optimized polyamine depletion regimens for activity against neuroblastoma.
|
27012811 |
2016 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we found miR-1303 was upregulated in NB cells and tissues, miR-1303 overexpression promoted the proliferation of SH-SY5Y NB cell investigated by MTT assay, colony formation assay and anchorage-independent growth ability assay, while miR-1303 knockdown reduced this effect. mechanism analysis suggested glycogen synthase kinase 3 beta (GSK3β) and secreted frizzled-related protein 1 (SFRP1) were the target of miR-1303, luciferase assay revealed miR-1303 directly bound to the 3'UTR of GSK3β and SFRP1. miR-1303 increased expression of MYC and CyclinD1, and decreased the expression of p21 and p27, and further demonstrated miR-1303 promotes NB proliferation.
|
27434867 |
2016 |
Central neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Amplification of the MYCN oncogene, a member of the MYC family of transcriptional regulators, is one of the most powerful prognostic markers identified for poor outcome in neuroblastoma, the most common extracranial solid cancer in childhood.
|
27448979 |
2016 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
|
27197232 |
2016 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Amplification of the MYCN is the predominant marker for aggressive NB and correlates with poor prognosis, while c-MYC overexpression is a defining feature of MB subgroups inflected with aggressive biological behavior and increased likelihood of metastasis.
|
26373717 |
2016 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Little is known regarding the prognostic significance of the homologous MYC protein expression in neuroblastoma.
|
26035700 |
2015 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Amplification or overexpression of neuronal MYC (MYCN) is associated with poor prognosis of human neuroblastoma.
|
26156430 |
2015 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Clinical data set analysis of MYCN, MYC and TWIST1 expression permits us to confirm that TWIST1 expression is upregulated in MYCN amplified neuroblastoma but also in a subset of neuroblastoma harboring high expression of MYCN or MYC without gene amplification.
|
25475555 |
2015 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In sharp contrast to MYCN, enforced expression of c-MYC did not enhance OCT4 expression in human neuroblastoma cells.
|
25880909 |
2015 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In MYC-amplified neuroblastoma patient samples, there was a significant correlation between SHMT2 and hypoxia-inducible factor-1 α (HIF1α), and SHMT2 expression correlated with unfavorable patient prognosis.
|
25186948 |
2014 |
Central neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MYCN and MYC play a crucial role in determining the malignancy of unfavorable neuroblastomas, whereas high-level expression of the favorable neuroblastoma genes is associated with a good disease outcome and confers growth suppression of neuroblastoma cells.
|
24173829 |
2014 |
Central neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TFs like MYC and PTEN having six types of adjacent nodes and other classes of TFs investigated really can help to demonstrate that TFs affect pathways through expressions of significant miRNAs involved in the pathogenesis of NB.
|
25292042 |
2014 |